Regenerative Medicineto reverse osteoporosis
Innovative drugs that rebuild bone lost to disease and trauma
Mesentech developed a novel drug conjugate* that can deliver bone growing drugs selectively to the bone. The drug is then released locally and in a sustained manner.
*C3 is the name of one of our drug-conjugate therapeutics in development.
Stepping Stones to The Futureof Bone Regeneration
Healthy bone architecture(100x)
Mesentech's bone anabolic drug conjugates will be incrementally developed first as a treatment for osteogenesis imperfecta, an orphan congenital disease that results in low density brittle bone, and will be followed by development for osteoporosis.
A topical formulation can be developed to serve as a general-purpose bone graft material to speed osseointegration in orthopedic and oral-maxillofacial indications while avoiding the cost and morbidity associated with harvesting self-donor material for autografts.
Learn more about our science
If you are interested in partnering, we’d love to hear from you.
Robert YoungFounder & President
• 30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®. Vioxx®, Arcoxia®, Previcox®, Tredaptive® and odanacatib • Recipient of Heros of Chemistry award and the Order of Canada award • Two time recipient of Prix Galien (UK and Canada)
• Head of Business Development at Novateur Ventures • Founder and former CEO of Datapoint Diagnostics • Co-founder of C7bio • Deep international experience in clinical development, financing, regulatory strategy, pharmaceutical partnerships, recruiting angel investors, asset sale and patenting • Speaks 5 languages having lived and worked in China, Israel, Brazil, US & Canada.
Michael UnderhillCo-founder & Chief Sceince Officer
• Leading foundational research on mechanisms underlying bone formation • Cofounder of Corigen and Nexigen • Professor of Microbiology & Immunology at UBC
Peter SavasExecutive Chairman
• Serial CEO with 8 positive exists for shareholders • Current CEO of Likeminds • Formerly CEO of Alseres Pharma • Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease • Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials • leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.
Meet the whole team